New hope for kids with Hard-to-Treat bleeding disorder
NCT ID NCT07214025
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This study tests a drug called romiplostim in 100 children aged 1 to 18 with chronic ITP, a condition where the immune system destroys platelets, causing bleeding. The drug aims to safely increase platelet counts to safe levels for at least 6 weeks out of 48, without needing rescue treatments like steroids or transfusions. Participants must have failed or not tolerated standard therapies and have very low platelets or active bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROMIPLOSTIM N01 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.